The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Stocks turned mostly lower as trade worries overshadowed a report that U.S. inflation slowed more than expected in February.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results